• Call(WhatsApp Us)

    +8615360806100
  • Email Us

    cherry@laeyo.com
  • 广州市花都区花山镇华辉路18号

    微观化妆品创意产业园E栋整栋

Private Label Facial Serum Ingredient Changes: Who Must Authorize Substitutions Before GCC Production?

A private label facial serum is rarely a “finished” formula. Actives get discontinued, a supplier changes its carrier grade, a fragrance house issues a new base version, and suddenly the factory needs a decision…

Category: Skincare Sourcing Guides • Author: laeyo • Published: 2026-11-12 • Views: 26

A private label facial serum is rarely a “finished” formula. Actives get discontinued, a supplier changes its carrier grade, a fragrance house issues a new base version, and suddenly the factory needs a decision before the next GCC production run. The question buyers ask most often is deceptively simple: who is actually allowed to approve that substitution? This guide answers it operationally — with a sign-off matrix, an evidence pack you can forward to your manufacturer today, a realistic timeline, and the failure modes that cause shipments to be held at the port or pulled from a launch calendar.

Informational only, not legal advice. Market classification and filing obligations must be confirmed with your in-market regulatory agent for each GCC state you sell into.

Quick answer: substitution authority is a matrix, not a single signature

  • What triggers the question: any change to a raw material’s supplier, site, grade, purity, carrier, or to the fragrance/preservative/colorant/solvent system — even when the INCI name stays identical. In a leave-on facial serum, these changes hit safety files, allergen declarations, label text, and consumer experience at the same time.
  • Three highest-leverage decisions first: (1) lock a formula version number that the manufacturer may not modify unilaterally; (2) classify the change as administrative, reformulation-lite, or full reformulation; (3) confirm in writing whether the change triggers a dossier or label update in each target GCC market.
  • Fastest safe path: freeze the packaging specification and the claim list first — they are cheap to lock and expensive to redo. Screening and lab work can start in parallel; safety review and in-pack compatibility cannot be skipped or compressed.
  • Evidence to request immediately: side-by-side specification and COA for old vs. new material; SDS; fragrance IFRA certificate and allergen declaration matched to the actual product use; accelerated stability plus in-pack compatibility protocol; and a written statement on whether the existing safety assessment and market notification remain valid.
  • Rule of thumb: a factory may propose a substitution. Only the brand owner, supported by a safety assessor and the in-market regulatory responsible entity, can authorize one that touches label, claim, safety file, or sensory performance.

Why “same INCI” is not a green light

An INCI name identifies a substance family, not a commercial material. Two lots with the same INCI can differ in active assay, salt form, solvent or carrier, particle size, degree of polymerization, impurity profile, color, odor, and preservative system. In a serum — where water content, pH, and electrolyte balance are already tight — those differences show up as viscosity drift, phase separation, haze in clear gel, or a change in how the product spreads and absorbs.

The minimum acceptable evaluation sequence for a same-INCI substitution is:

  • COA and specification comparison (assay, impurities, pH, appearance, odor)
  • Lab trial at the proposed use level in the actual formula
  • Key stability checkpoints plus viscosity, pH, and appearance
  • Sensory and application evaluation (spreadability, absorption, tack, residue)
  • Preservative efficacy and efficacy testing only if the change can affect them
  • Cost and supply review — last, not first

Who must authorize: the sign-off matrix

Change type Who must authorize Hard evidence required before bulk production
New supplier, same INCI, same grade and site-verified equivalence Brand owner (formula owner) + manufacturer QA; regulatory informed in writing Side-by-side spec and COA, lab trial result, stability checkpoints
Different grade, purity, carrier, or manufacturing site Brand owner + safety assessor + regulatory Full equivalence dossier, accelerated stability, updated safety file statement
Active concentration change Brand owner + safety assessor + regulatory New formula version, stability, efficacy or claim support review
Preservative system change Safety assessor (lead) + brand owner Preservative efficacy test in final pack, pH and micro data
Fragrance base version or fragrance supplier change Brand owner + safety assessor + regulatory IFRA certificate matched to actual use (rinse-off vs. leave-on), allergen declaration, exposure re-assessment
Colorant change Regulatory first, then brand owner Market-by-market permitted colorant confirmation; not treated as an ordinary ingredient
Bottle, dropper, pump, gasket, dip tube, or coating change Brand owner + packaging supplier + QA In-pack compatibility and fill test, component drawings and material specs
Label text, INCI order, or claim wording change Brand marketing + regulatory claim review Claim matrix with evidence ID and artwork release record

Decision tree: classify your change in 60 seconds

START HERE
1. Is it the same INCI, same grade, same supplier site, documented in writing?
   YES -> Administrative re-qualification: COA compare + lab trial + stability checkpoints.
          Sign-off: manufacturer QA + brand operations. Regulatory notified, not asked.
   NO  -> Continue.
2. Does the change touch fragrance, preservative, colorant, ethanol/denatured solvent,
   or the antioxidant system?
   YES -> Full safety re-review. Safety assessor leads. Do not schedule bulk.
   NO  -> Continue.
3. Does it change any label statement, INCI order, allergen declaration, or claim?
   YES -> Stop. Label and claim review before any production date is confirmed.
   NO  -> Continue.
4. Does it change viscosity, pH, color, odor, fill weight, or pump/dropper performance?
   YES -> In-pack compatibility and fill test on the production component.
5. Is the SKU already notified or registered in a GCC market?
   YES -> Ask the in-market agent, in writing, whether an update or re-notification is needed.
BOUNDARY CASES -> drug-boundary claims, nano materials, color additives, or a new active
not previously assessed: use specialist counsel, extra testing, or an alternative pathway.

Minimum evidence pack to request before GCC production

A) Compliance and filings

  • Request: the controlled formula version number and a written change description naming old vs. new material, supplier, grade, and site.
    Evidence: version-controlled formula record plus side-by-side specification.
    Owner: Manufacturer.
    Acceptance criteria: one document listing INCI, CAS where applicable, grade, supplier, and site for both materials — no bare “equivalent” wording.
  • Request: a written statement from the in-market regulatory agent per GCC market on whether the change triggers a dossier update, re-notification, or Arabic label revision.
    Evidence: market-by-market regulatory assessment with the specific document to be resubmitted.
    Owner: Buyer / regulatory agent.
    Acceptance criteria: explicit yes/no per market, dated and signed.
  • Request: confirmation that product classification is unchanged (cosmetic vs. drug-boundary).
    Evidence: signed classification note referencing the approved claim list.
    Owner: Regulatory.
    Acceptance criteria: classification note dated after the change request, not before.

B) Testing and substantiation

  • Request: COA comparison and accelerated stability in the final pack.
    Evidence: stability protocol with checkpoints at agreed intervals, plus viscosity, pH, and appearance data.
    Owner: Lab.
    Acceptance criteria: all checkpoints within the approved specification window; no separation, haze, or odor deviation.
  • Request: preservative efficacy test if preservative, pH, or packaging changed.
    Evidence: challenge test report against the applicable pharmacopoeial or internal criteria.
    Owner: Lab.
    Acceptance criteria: criteria met in the production pack, not a lab jar.
  • Request: finished-product evidence for any claim that links the changed ingredient to an outcome.
    Evidence: product-level study or substantiation file.
    Owner: Manufacturer / lab / brand.
    Acceptance criteria: the study tests the finished formula at the marketed use level — ingredient papers do not transfer.

C) Labeling and claims guardrails

  • Request: updated INCI list in correct descending order with allergen declaration.
    Evidence: label proof with the allergen statement calculated from the new fragrance or material declaration.
    Owner: Buyer / regulatory.
    Acceptance criteria: declaration matches the actual fragrance version in the bill of materials — version-to-version match, not a prior certificate.
  • Request: claim matrix separating factual ingredient statements (“contains niacinamide”) from finished-product claims (“improves skin comfort”).
    Evidence: claim matrix with evidence ID per line.
    Owner: Brand marketing / regulatory.
    Acceptance criteria: no claim on pack, website, or influencer brief without an evidence ID.

D) QA, traceability, and audit readiness

  • Request: change control record with named approvers and dates.
    Evidence: signed change control form referencing the formula version.
    Owner: Manufacturer QA.
    Acceptance criteria: brand signature present before the pilot batch is scheduled.
  • Request: supplier qualification file for the new material.
    Evidence: SDS, specification, allergen statement, and audit or approval status.
    Owner: Manufacturer / supplier.
    Acceptance criteria: file complete and dated within the supplier requalification cycle.
  • Request: pilot batch record and retention sample plan.
    Evidence: batch record showing the new lot number, plus retention samples of pilot and first commercial batch.
    Owner: Manufacturer QA.
    Acceptance criteria: lot traceability from raw material to finished unit; retention samples stored under defined conditions.

Evidence Pack Summary

  • Side-by-side specification and COA for old vs. new material, with supplier and site named.
  • Controlled formula record showing the new version number and approval signatures.
  • SDS for the new material, plus allergen statement if fragrance or botanical derived.
  • IFRA certificate matched to the actual product use category (leave-on serum, not shampoo).
  • Accelerated stability report with viscosity, pH, appearance, and odor checkpoints.
  • In-pack compatibility and fill test report using the production bottle, dropper, and gasket.
  • Preservative efficacy test report, where the change can affect the preservative system.
  • Finished-product claim substantiation file for every performance claim retained.
  • Updated label proof with INCI order and allergen declaration verified against the bill of materials.
  • Written market-by-market regulatory assessment for each GCC destination.
  • Signed change control record and pilot batch record with lot traceability.

Timeline: fastest safe path vs. standard path

Phase Buyer action Manufacturer action Evidence output Fastest safe Standard
0. Change request and classification Submit written change request with target markets and SKU list Issue change control form and equivalence screen Signed change request, classification note 2–3 days 3–5 days
1. Equivalence screen and lab trial Approve trial brief and use level COA comparison, lab batch, sensory panel Comparison table, trial batch record, sensory notes 5–10 days 2 weeks
2. Safety and regulatory review Obtain in-market agent statement per GCC state Update safety assessment inputs, allergen calculation Safety file statement, regulatory assessment 5–10 days (parallel) 2–3 weeks
3. Stability and in-pack compatibility Lock packaging specification and component drawings Accelerated stability and fill test in production pack Stability report, compatibility report 4 weeks accelerated (real-time continues) 8–12 weeks
4. Claim and label lock Approve claim matrix and artwork Verify INCI order and allergen text against BOM Approved artwork release record 3–5 days 1–2 weeks
5. Pilot run Approve pilot samples against golden reference Run pilot batch, retain samples Pilot batch record, retention samples 1 week 2 weeks
6. Documentation handoff Confirm dossier completeness with agent Compile COA, SDS, stability, compatibility, batch records Complete documentation pack 3–5 days 1 week

What may be compressed: paperwork sequencing, parallel lab and regulatory review, and the number of pilot iterations — provided the golden reference sample is unambiguous. What may not: safety review, allergen calculation, in-pack compatibility, and preservative efficacy where relevant.

Do NOT cut: quality, safety, and compliance red lines

  • Do not accept a substitution on the basis of INCI identity alone — require the specification and COA comparison.
  • Do not approve a fragrance change without an IFRA certificate written for the actual use category and an updated allergen declaration.
  • Do not skip in-pack compatibility because bulk passed — the dropper, gasket, and coating are part of the product.
  • Do not carry forward a preservative efficacy result after a preservative, pH, or packaging change.
  • Do not carry forward a finished-product claim from an ingredient study. Ingredient data is not finished-product evidence.
  • Do not treat a notification or registration as approval of marketing claims.
  • Do not let the factory substitute at bulk stage without a signed change control record. Ever.

Common failure modes

1. Packaging compatibility failure: dropper gasket swells and the serum weeps

  • Symptom: leakage at the collar after two weeks in transit; inconsistent drop dose.
  • Root cause: only bulk was tested; the new solvent or fragrance interacted with the gasket elastomer or the dropper coating.
  • Prevention: fill test in the production component for a defined period at defined temperatures, including inverted storage.
  • What to request from factory (Evidence): in-pack compatibility report, component drawings, gasket and liner material specification.

2. Documentation failure: COA does not match the material in the tank

  • Symptom: incoming COA lists a different grade, assay, or supplier than the approved specification; INCI on the label no longer matches the BOM.
  • Root cause: no document gate at goods-in; substitution made at purchasing level and never entered change control.
  • Prevention: a goods-in documentation gate with a defined rejection rule, plus a monthly BOM-to-label reconciliation.
  • What to request from factory (Evidence): supplier qualification file, lot-linked COA, SDS, and the signed change control record for the current formula version.

3. Viscosity or phase drift after a “same INCI” swap

  • Symptom: serum thins or thickens; a clear gel turns hazy; slight separation at the shoulder.
  • Root cause: differences in polymer grade, electrolyte content, or carrier solvent between suppliers.
  • Prevention: lab trial plus stability checkpoints before any bulk commitment.
  • What to request from factory (Evidence): stability report with viscosity, pH, and appearance data across checkpoints.

4. Fragrance base version change invalidates the allergen declaration

  • Symptom: label allergen statement does not match the fragrance actually used; consumer complaints about irritation.
  • Root cause: fragrance house issued a new base version or the supplier changed; documentation was not refreshed.
  • Prevention: treat fragrance base version and IFRA certificate changes as mandatory revalidation triggers.
  • What to request from factory (Evidence): current IFRA certificate for the leave-on category, allergen declaration, and exposure re-assessment note.

5. Preservative change without a new challenge test

  • Symptom: micro out-of-spec on a retention sample; recall risk in warm-climate distribution.
  • Root cause: preservative substituted on cost or supply grounds; efficacy assumed from the previous system.
  • Prevention: any preservative, pH, or packaging change triggers a preservative efficacy test.
  • What to request from factory (Evidence): challenge test report in the production pack with pass criteria stated.

6. Regulatory review happens after the purchase order

  • Symptom: shipment ready but the market dossier still describes the old formula; launch date slips.
  • Root cause: change treated as a purchasing decision rather than a filing event.
  • Prevention: written in-market agent statement before bulk is scheduled, per destination market.
  • What to request from factory (Evidence): regulatory assessment per market naming the documents requiring resubmission.

7. Claim creep: “clinically proven” borrowed from an ingredient paper

  • Symptom: website copy outruns the dossier; advertising scrutiny or marketplace takedown.
  • Root cause: ingredient story and finished-product claim managed in the same document.
  • Prevention: a claim matrix with evidence IDs; ingredient facts and performance claims kept in separate columns.
  • What to request from factory (Evidence): finished-product study or substantiation file for each retained performance claim.

8. Color or odor shift in a clear glass bottle

  • Symptom: batch-to-batch tint variation visible on shelf; returns and review complaints.
  • Root cause: antioxidant system or botanical extract source changed; specification had no color or odor tolerance.
  • Prevention: add measurable color and odor acceptance criteria to the raw material specification.
  • What to request from factory (Evidence): specification with color/odor limits and reference standard samples.

Copy-paste substitution request checklist

Subject: Ingredient substitution request - facial serum - approval required before bulk

Share the controlled formula version number and the SKU list affected.
Describe the change: old material vs new material, supplier, grade, and site.
Attach side-by-side specification and COA for both materials.
Attach SDS for the new material.
State whether fragrance, preservative, colorant, solvent, or antioxidant system is affected.
Provide the IFRA certificate and allergen declaration if fragrance is affected.
Confirm the IFRA category matches a leave-on facial serum, not a rinse-off product.
Provide the proposed use level and confirm it matches the approved formula.
Run a lab trial and share viscosity, pH, appearance, and odor results.
Provide the accelerated stability protocol and checkpoint schedule.
Provide the in-pack compatibility protocol using the production bottle and dropper.
Confirm whether a preservative efficacy test is required, and why or why not.
List every label element that changes: INCI order, allergen text, warnings, claims.
Provide the finished-product evidence for each performance claim retained.
Confirm whether any GCC market notification or dossier needs updating.
Provide a written regulatory assessment per destination market.
Submit the signed change control record with named approvers.
Confirm the pilot batch date only after brand approval is logged.
Provide retention sample quantities and storage conditions.
Attach the goods-in documentation gate rule for the new material.
Confirm the golden reference sample for sensory comparison.
State the earliest bulk date after all approvals are complete.

Summary: substitution levers and their red lines

Lever / Decision Primary impact What to do (specific) Do NOT cut (red line) Evidence needed (request) Expected timeline effect
Accept a same-INCI supplier swap Cost and supply continuity Run COA comparison plus lab trial at approved use level before scheduling bulk Specification and COA comparison with assay and impurity limits Side-by-side spec and COA, trial batch record Adds 1–2 weeks; avoids 4+ week rework
Change fragrance base version Safety file, allergen label, sensory identity Re-issue allergen calculation and confirm IFRA category for leave-on use IFRA certificate matched to actual use plus allergen declaration IFRA certificate, allergen statement, exposure note Adds 1–2 weeks to label lock
Change preservative system Microbial safety Commission a preservative efficacy test in the production pack Challenge test pass criteria in final packaging Preservative efficacy test report Adds 3–4 weeks; non-negotiable
Change dropper or bottle component Leak risk, dose consistency, label adhesion Fill test in production components with inverted storage In-pack compatibility test with gasket and coating specs Compatibility report, component drawings Adds 4 weeks accelerated
Compress stability testing Launch speed Use accelerated conditions with real-time running in parallel, not instead Minimum accelerated checkpoints at defined intervals Stability protocol and checkpoint data Saves 4–6 weeks only if real-time continues post-launch
Retain performance claims Marketing copy and marketplace compliance Map each claim to a finished-product evidence ID before artwork approval Finished-product substantiation at marketed use level Claim matrix with evidence IDs, study report Prevents late-stage copy pull; may add 2 weeks
Defer GCC regulatory check Market release Get written market-by-market assessment before the pilot batch Per-market regulatory statement on dossier and label updates Signed regulatory assessment Avoids 2–6 week hold at shipment
Allow factory-side substitution at bulk Formula integrity and audit standing Require signed change control before any material enters the tank Brand signature on change control record Signed change control, lot-linked COA Prevents full-batch rejection
Pilot run before documentation lock Cost of rework Sequence pilot after label lock and safety review, not before Approved artwork release and safety statement Artwork release record, safety file statement Saves one full pilot iteration

FAQ

Can my manufacturer substitute an ingredient if the INCI name is identical?

No. The factory can propose a substitution, but identical INCI does not mean identical material. Assay, grade, carrier, impurities, and site can all shift performance and safety. A written equivalence screen, lab trial, and stability checkpoints are the minimum before approval — and the brand owner must sign.

Who signs off — the brand or the factory?

Both, in different lanes. The brand owner authorizes anything that changes the formula, label, claim, or consumer experience. The safety assessor owns the safety conclusion. The in-market regulatory responsible entity owns the filing position. Manufacturer QA owns batch-level traceability. No single party can authorize a change alone.

Does a GCC market notification need updating after a substitution?

It depends on the material changed, the market, and how the product is classified there. This must be answered in writing by your in-market agent for each destination — not assumed. Build that written statement into the approval gate before bulk is scheduled.

Can we skip stability if only the supplier changed?

No. Supplier changes are a standard revalidation trigger. At minimum, run COA comparison, a lab trial, stability checkpoints, and in-pack compatibility. If the change touches preservative, pH, or packaging, add a preservative efficacy test.

How long does a well-run substitution take?

Roughly 4–6 weeks on the fastest safe path where the change is administrative and documentation is clean, and 8–12 weeks on the standard path when stability, in-pack compatibility, and regulatory updates are in scope. Most delays come from documentation gaps, not from the lab.

Next step

If you are planning a facial serum substitution for a GCC launch, send us the change description, the target markets, the SKU and format list, your positioning, the packaging direction, and your timeline target. That combination is what allows a formulation and compliance team to return a scope, an evidence list, and a realistic production window instead of a generic price sheet.

Request a Quote

Hi, I'm your LAEYO representative, hope you like this blog post.

With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.

  • Our team will answer your inquiries within 8 hours.
  • Your information will be kept strictly confidential.

Request received

Thanks — we’ve received your request. Our team will follow up shortly. we typically reply within 8 hours (often sooner).